Phase 2, randomized, open-label study of trilaciclib co-administered with first-line platinum-containing chemotherapy and avelumab maintenance therapy in patients with locally advanced or metastatic urothelial carcinoma
COMMERCIAL CLINICAL TRIAL
Clinical trial information
- Promoter: G1 THERAPEUTICS
- Phase: II
- Execution start: 20/10/2021
- End of execution: 30/10/2023
- PI: RAQUEL LUQUE CARO